Published in Med Clin (Barc) on February 01, 2003
Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. Med Decis Making (2011) 0.97
Comparing the health of low income and less well educated groups in the United States and Canada. Popul Health Metr (2007) 0.89
Prioritisation of patients on waiting lists for hip and knee arthroplasties and cataract surgery: Instruments validation. BMC Health Serv Res (2008) 0.84
Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3. Pharmacoeconomics (2016) 0.81
Comparing population health in the United States and Canada. Popul Health Metr (2010) 0.79
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res (2006) 1.88
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy (2010) 1.69
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry (2009) 1.61
Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J (2013) 1.57
Cognitive function impairment in patients with neuropathic pain under standard conditions of care. J Pain Symptom Manage (2007) 1.50
Advances in behavioral genetics modeling using Mplus: applications of factor mixture modeling to twin data. Twin Res Hum Genet (2006) 1.28
A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol (2011) 1.21
Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). Value Health (2008) 1.18
Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes (2010) 1.14
Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes (2007) 1.11
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res (2010) 1.09
Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther (2009) 1.05
Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord (2008) 1.03
Longitudinal stability of the CBCL-juvenile bipolar disorder phenotype: A study in Dutch twins. Biol Psychiatry (2006) 1.01
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res (2008) 1.01
Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. J Clin Epidemiol (2007) 0.99
Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis (2010) 0.99
Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord (2010) 0.96
Complex span tasks, simple span tasks, and cognitive abilities: a reanalysis of key studies. Mem Cognit (2006) 0.95
[Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain]. Med Clin (Barc) (2006) 0.94
Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat. Ophthalmic Epidemiol (2010) 0.94
Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care (2002) 0.93
Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int (2009) 0.92
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain (2006) 0.92
The assessment of generalized anxiety disorder: psychometric validation of the Spanish version of the self-administered GAD-2 scale in daily medical practice. Health Qual Life Outcomes (2012) 0.91
Consistency errors in p-values reported in Spanish psychology journals. Psicothema (2013) 0.91
Development and validation of the Migraine Screen Questionnaire (MS-Q). Headache (2005) 0.89
Mutation analysis of the LCE3B/LCE3C genes in Psoriasis. BMC Med Genet (2010) 0.89
Using the WHOQOL-BREF in persons with dementia: a validation study. Alzheimer Dis Assoc Disord (2011) 0.86
Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. BMC Musculoskelet Disord (2009) 0.85
Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur Neuropsychopharmacol (2011) 0.85
Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study. Clin Drug Investig (2009) 0.85
New uses of the Migraine Screen Questionnaire (MS-Q): validation in the Primary Care setting and ability to detect hidden migraine. MS-Q in Primary Care. BMC Neurol (2010) 0.84
[Prevalence of neuropathic pain in Spain: clinical, working and health care implications]. Med Clin (Barc) (2005) 0.84
Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophr Res (2007) 0.84
Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. Clin Drug Investig (2006) 0.83
Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement? Ann Gen Psychiatry (2011) 0.83
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res (2011) 0.82
Rapid detection of sepsis in rats through volatile organic compounds in breath. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.82
Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials. Rev Psiquiatr Salud Ment (2011) 0.82
Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). BMC Med Res Methodol (2011) 0.82
Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ (2009) 0.81
Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med (2010) 0.81
Substantial genetic link between IQ and working memory: implications for molecular genetic studies on schizophrenia. the European twin study of schizophrenia (EUTwinsS). Am J Med Genet B Neuropsychiatr Genet (2013) 0.81
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol (2011) 0.81
The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study. Community Ment Health J (2012) 0.81
Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study. Soc Psychiatry Psychiatr Epidemiol (2004) 0.81
Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form. Clin Drug Investig (2012) 0.80
Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms. Pharm World Sci (2005) 0.80
Detecting changes in patient treatment satisfaction with medicines: the SATMED-Q. Value Health (2013) 0.80
Trigeminal neuralgia treated with pregabalin in family medicine settings: its effect on pain alleviation and cost reduction. J Clin Pharmacol (2009) 0.80
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ (2004) 0.80
A confirmatory study of the Combined Index of Severity of Fibromyalgia (ICAF*): factorial structure, reliability and sensitivity to change. Health Qual Life Outcomes (2011) 0.80
Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. Schizophr Res (2012) 0.80
Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). Schizophr Res (2009) 0.80
Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon Outcomes Res (2012) 0.79
Modeling the predictive value of pain intensity on costs and resources utilization in patients with peripheral neuropathic pain. Clin J Pain (2015) 0.79
Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis. Pain Pract (2011) 0.79
Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. Clin Drug Investig (2012) 0.79
Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health Qual Life Outcomes (2009) 0.79
Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain. Epilepsy Res (2008) 0.79
Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res (2008) 0.79
Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain. Clin J Pain (2013) 0.79
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.79
[Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder]. Med Clin (Barc) (2012) 0.78
Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol. Clin Drug Investig (2012) 0.78
[Linguistic adaptation into Spanish and validation of the Arthritis Treatment Satisfaction Questionnaire]. Med Clin (Barc) (2005) 0.78
Structural validity of a 16-item abridged version of the Cervantes Health-Related Quality of Life scale for menopause: the Cervantes Short-Form Scale. Menopause (2015) 0.78
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. BMC Urol (2013) 0.77
An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes (2012) 0.77
A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain. Pain Med (2012) 0.77
Validation of the Spanish version of the DEMQOL system. Int Psychogeriatr (2010) 0.77
Linguistic adaptation and validation into Spanish of the Diagnostic Interview for Borderline Personality Disorders-Revised (DIB-R). Curr Med Res Opin (2005) 0.77
Criterion validity of the ARthritis Treatment Satisfaction (ARTS) questionnaire: patient satisfaction with treatment and need for switching therapy. Clin Drug Investig (2009) 0.76
A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings. Pain Pract (2010) 0.76
Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig (2014) 0.76
A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis. Int J Oncol (2004) 0.76
Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. Soc Psychiatry Psychiatr Epidemiol (2012) 0.76
[Linguistic adaptation into Spanish and psychometric validation of the ID-Pain questionnaire for the screening of neuropathic pain]. Med Clin (Barc) (2008) 0.76
A 6-week training program increased muscle antioxidant system in elderly diabetic fatty rats. Med Sci Monit (2012) 0.76
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy. Epigenetics (2014) 0.76
Is rosuvastatin really a more efficient therapeutic option than atorvastatin? Value Health (2006) 0.75
[Voriconazol and liposomal amphotericin B: true evidence of their differences with regard to effectiveness and safety]. Med Clin (Barc) (2005) 0.75
Reboxetine addition in patients with mirtazapine-resistant depression: a case series. Clin Neuropharmacol (2006) 0.75
Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics (2006) 0.75
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. Ann Clin Psychiatry (2013) 0.75